Clinical Trial

Patients With Necrotizing Skin and Soft Tissue Infections Managed Within the SURFAST Care Pathway.

Study acronym: SURFAST
Not Yet Recruiting
View on ClinicalTrials.gov →
Summary
Necrotising soft-tissue infections (NSTIs) are rare and life-threatening skin and soft tissue infections requiring urgent combined medical and surgical management in specialist centres. At Assistance Publique-Hôpitaux de Paris, a multidisciplinary reference network called the SURFAST consortium has been established. This network includes experts in the management of NSTIs, such as intensivists, dermatologists, infectious disease physicians, paediatricians, surgeons, and microbiologists. The consortium manages all NSTI cases referred from the greater Paris area, a large region of France with a population exceeding 12 million. The SURFAST network comprises care pathways enabling the management of adult and paediatric patients with abdomino-perineal, limb, and cervico-facial NSTIs. All patients managed within this care pathway are included in a prospective, multicentre cohort study. This study examines factors associated with mortality at day 90, long-term sequelae, quality of life, and indicators of the quality of care.
Trial Details
NCT Number NCT07417982
Lead Sponsor Assistance Publique - Hôpitaux de Paris
Conditions Necrotizing Soft-tissue Infections
Enrollment 1,000 participants
Start Date 2026-03-01
Primary Completion 2036-06-01 (estimated)
Study Completion 2036-06-01 (estimated)
Updated on ClinicalTrials.gov 2026-02-18